To show that macrophages can be effectively targeted against malignant B cells, bispecific antibodies (BsAb) were constructed from two antibodies having specificity for the high-affinity Fc receptor for IgG (FcyRIICD64) and the B-cell differentiation antigens CD19 and CD37. Using a flow cytometry-based assay and confocal imaging, we show that these constructs mediated significant phagocytosis of B lymphocytes by macrophages that could be enhanced with interferon y ClFNy) and IFNy in combination with macrophage colony-stimulating factor. BsAb-dependent phagocytosis was triggered through FcyRl and could be blocked only by using F(ab'), fragments from the parent molecule or by cross-linking FcyRI. BsAb-dependent phagocytosis was not blocked ESPITE IMPROVEMENTS in complete remission
D rates due to the use of high-dose combination chemotherapy with or without bone marrow and stem cell support, the majority of patients with non-Hodgkin's lymphoma (NHL) will die of their disease.'.' Therefore, immunologic approaches to NHL have been studied intensively in recent years. Anti-idiotypic antib~dies,~.~ unlabeled monoclonal antibodies (MoAbs)?-* and antibodies conjugated to various toxin^^.'^ or radioisotope^'^^" have shown promise. However, transient responses, inefficiency of killing, or toxicity have slowed their application in the clinical setting. An approach that retains the specificity of MoAb therapy and that enhances target cell destruction without toxicity would have great therapeutic potential. This would particularly benefit those patients who could not tolerate additional organ toxicity due to age, immunodeficiency, or previous damage from standard chemotherapeutic regimens. Bispecific antibodies (BsAbs) may provide such a method to harness an effector population and redirect cytotoxicity to a malignant cell target while minimizing systemic toxicity.
BsAbs are constructed such that two antibodies are joined to form a single molecule having specificity for both the effector cell and the target cell." Trigger molecules on cytotoxic effector cells include the T-cell receptor, CD2, CD3, and the Fc receptors for IgG (FcyR) . One focus of tumordirected BsAb studies that has shown promise both in vitro and in vivo has involved targeting lymphocytes (T cells via anti-CD3 or anti-CD2 or natural killer [NK] cells via anti-CD16) as effector cell^.^^-^^ Like the cytotoxic T lymphocyte or NK cell, the macrophage (Ma) may also serve as a cytotoxic effector cell that can be directed by BsAb. M 0 constituitively express and can mediate killing through all three classes of FcyR (FcyRI, FcyRII, and FcyRIII) either by phagocytosis or external killing. '9,22,23 In fact, several clinical trials are now in progress in which BsAb are being used to direct monocyte, M a , andor activated neutrophil killing of human tumors in
The studies presented here focus on BsAb-mediated M 0 phagocytosis through Fc yRI. Because of the avid binding of monomeric IgG to FcyRI, antitumor cell-directed MoAb may be competitively inhibited in vivo from binding to this receptor. To circumvent this problem, MoAbs (such as MoAb32 and MoAb22) that bind to FcyRI outside its ligand by antibodies to the other Fc receptors, FcyRll and FcyRIII. Because these antibody constructs bind to an epitope outside the FcyRl ligand binding site, we show that autologous serum, polyclotial IgG, and monomeric lgGl did not block BsAb-dependent phagocytosis, whereas autologous serum and the IgG fractions blocked parent molecule monoclonal antibody-dependent phagocytosis due to the avid binding of monomeric IgG to FcyRI. Finally, BsAb-mediated phagocytosis was effective against the malignant B cells of patients with mantle cell lymphoma, prolymphocytic leukemia, and chronic lymphocytic leukemia. Based on these studies, we propose that BsAbs may provide an effective means of immunomodulation for patients with B-cell malignancies. 0 1996 by The American Society of Hematology.
binding site are being used in the construction of BsAbs targeting Fc~RI.'~*'' BsAbs constructed with these MoAbs are able to effectively mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis of tumor cells even in the presence of human serum. In this report, we use BsAbs specific for FcyRI and the pan-B-cell markers CD37 and CD19 to show that activated M 0 can be effectively targeted to mediate phagocytosis of patient-derived malignant lymphocytes even in the presence of nonspecific human IgG.
4 ELY ET AL
Berkeley, CA). The aggregated cells were sedimented at Ig on ice for 10 minutes, gently resuspended in 2 mL of RPMI. and layered onto an equal volume of ice-cold fetal calf serum (FCS). After sedimentation for 15 minutes on ice, the lower phase was collected, washed twice in Versene buffer (GIBCO). and washed twice in CM. Purity was confirmed by Wright stained cytocentrifuge preparations and ranged between 85% to 95% monocytes, with the remainder being lymphocytes.
Monocyte-derived M 0 (MDM0) were obtained by culturing monocytes as a nonadherent suspension in Teflon beakers (Savillex, Inc, Minnetonka, MN) for 8 to 10 days at a concentration of 4 x IO6 cellslmL in RPMI 1640 (Sigma) supplemented with 50 mmol/ L HEPES. 2 mmol/L fresh glutamine, and 2.5% autologous serum. Venous blood was collected separately as a source of autologous serum.
Malignant lymphocytes were obtained from the peripheral blood of consenting patients with circulating lymphoma cells or chronic lymphocytic leukemia (CLL). Malignant lymphocytes were purified on Ficoll-Hypaque and frozen in a solution consisting of 45% RPMI, 45% FCS, and 10% dimethyl sulfoxide (Fisher, Fair Lawn, NJ) and stored at -80°C until needed. P24 was from a patient with mantle cell lymphoma, P49 was from a patient with prolymphocytic leukemia, and P61 through P64 were from patients with CLL. Raji cells, derived from a Burkitts lymphoma, were obtained from ATCC (Rockville, MD).
MoAbs. All MoAbs were of murine origin. The development and properties of MoAbs 22 (IgGl) and 197 (IgG2a), which both recognize the high-affinity FcyR12'; MoAb IV.3 (IgG2b). which recognizes F~y R 1 1~~; and MoAb 3G8 (IgGI), which recognizes F c~R I I I ,~ have been previously reported. Hybridomas producing antibodies to the B-cell differentiation antigens used in this study included the anti-CD19 MoAb FMC-63 (IgG2a; kindly provided by Dr Heddy a l a , Child Health Research Institute, Flinders University, Adelaide, Australia)" and the anti-CD37 MoAb WR17 (IgG2a; gift of Dr Martin Glennie, Tenovus Research Laboratory, Southampton General Hospital, Southampton, UK).'2 MoAbs were purified from hybridoma supernatant by ion exchange high-performance liquid chromatography (HPLC) on a (protein-pak 5PW) diethyl aminoethyl (DEAE) column (Waters Chromatography Division, Millipore, Milford, MA).
Human IgGl was obtained from the Serum of a myeloma patient by ion-exchange chromatography using Affi-Gel Blue (BioRad, Richmond, CA). The source for polyclonal Ig was commercially available Gamimune N (Miles, Inc, Elkhart, IN).
BsAh production. The BsAbs, anti-CD19xMoAb22, antiCD37xMoAb22, and 520C9xMoAb22, were constructed as described by Glennie et allR using the bifunctional cross-linking reagent, ortho-phenylenedimaleide (0-PDM; Sigma), to join Fab' fragments via stable thioether linkages (Fig I) . BsAb purity was assessed by nonreducing sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE). Product was further subjected to a bifunctional immunoassay to ascertain that both moieties were linked and functional. Briefly, BsAbs were incubated with Raji cells, which express both CD19 and CD37, and then washed, followed by the addition of a soluble fusion protein consisting of the extracellular domain of human FcyRI and human IgM heavy chain (sFcyRI-M) obtained from transiently transfected COS cells. Fluorescein isothiocyanate (FITC)-labeled goat-antihuman IgM was added and binding was assayed by flow cytometry. Only BsAb bound to Raji cells and the sFcyRI-M would remain in the assay and be FITC-positive. Both BsAbs were positive, whereas the parental antibodies (MoAb22, anti-CDI9, and anti-CD37) were negative in this assay.
Phagocytic assay. A modification of the two-color flow cytometric assay as described by Munn et al" was used to assess BsAbmediated phagocytosis of malignant lymphocytes. On day I, MDM0 effectors were harvested from Teflon beakers by vigorous pipetting, washed free of human serum, and resuspended in CM. MDM0s were counted and transferred to sterile, polypropylene, conical microtubes (Starstedt, Pennsauken. NJ) at a density of 3 to 5 X I@ effectors per tube in a volume of 200 pL. M 0 were incubated ovemight in CM (control) or with 160 U of human recombinant interferon y (rlFNy; generously provided by Genentech. South San Francisco, CA) alone or in combination with 100 ng/mL macrophage colonystimulating factor (M-CSF; a generous gift of Immunex Corp, Seattle, WA) as indicated.
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At the same time, malignant lymphocytes were quickly thawed in a 37°C water bath and labeled with PKH-26 (Zynaxis, Inc, Malvern, PA), a red fluorescent lipophilic dye that stably inserts into the cell membrane, as previously descriW.3' Washed cells were resuspended in supplied diluent and immediately combined with an equal volume of PKH-26 in diluent. Final staining conditions were 1 x lo7 cells/mL in 5 pmol/L PKH-26. After 5 minutes at room temperature, an equal volume of FCS was added to stop the staining reaction. Stained cells were washed twice with CM, transferred to T25 culture flask, and incubated in CM at 37°C overnight to eliminate any spontaneous leakage of dye during the phagocytosis assay.
On day 2, MDM0 were washed twice to remove cytokine and resuspended in fresh CM. BsAb and stained lymphocyte targets were sequentially added to each microtube and routinely incubated in a final volume of 200 pL at 37°C for 60 minutes. Unless otherwise indicated, the final BsAb concentration was 0.1 pg/mL and an effector to target ratio of approximately 10 to 1 was used. In some experiments, MDM0 were preincubated for 10 minutes with blocking antibodies at a final concentration of 200 pg/mL before adding BsAb and targets. At the completion of each experiment, microtubes were immediately placed on ice.
Phagocytosis was assayed by flow cytometry after labeling the M 0 with FITC-conjugated anti-CD14 (Medarex, Inc, Annandale, NJ). Briefly, the contents of each microtube were transferred to 96-well polypropylene plates (Costar, Cambridge, MA) and washed in FCM buffer (phosphate-buffered saline [PBS], pH 7.2, with 1% bovine serum albumin, 0.1% sodium azide, and 40 pg/mL disodium ethylenediamine-tetraacetic acid; Sigma). Cells were labeled for 30 minutes on ice with anti-CD14-FITC (20 pg/mL) in the presence of human IgG (6 mg/mL; Sigma) to reduce nonspecific antibody binding. They were washed three times with FCM buffer, fixed with 1% EM grade formaldehyde (Polysciences, Inc, Warrington, PA) in PBS, and stored refrigerated no longer than 1 week before analysis.
Labeled cells were analyzed on a FACScan (Becton Dickinson, San Jose, CA). Linear forward scatter versus logarithmic side scatter displays were used to set a broad gate that eliminated small debris and large aggregates before collection of list mode data. FITClabeled, CD14' MO were detected using logarithmic amplification 21) X 100%. Specific BsAb-mediated phagocytosis was calculated by subtracting the percentage of nonspecific phagocytosis occumng in the absence of antibody from the total amount of phagocytosis occumng in the presence of BsAb. All tests were conducted in triplicate and the results are expressed as the mean 5 standard deviation (SD). Statistical comparisons were made using a paired Student's t-test. P values less than .05 were considered to be statistically significant.
Representative samples were examined by fluorescent microscopy to confirm that tumor cells had been ingested and to rule out that target cells had merely bound to MDM0 without undergoing phagocytosis. In a standard 1-hour assay, greater than 85% of dual-positive MDM0 exhibited evidence of tumor cell ingestion.
To confirm that the dual-positive particles in the flow cytometric assay represented true phagocytosis of tumor
Confocal imaging.
cells by M0, dual-positive cells were sorted and examined by confocal microscopy. After fixation and flow cytometric analysis as described above, the dual-positive cells were sorted with a FACStar Plus flow cytometer (Becton Dickinson), centrifuged, and then placed on glass slides for imaging with a Meridian Ultima Laser Confocal cytometer (Meridian Instruments, Okemos, MI). Cells, located by their transmitted light image, were scanned for fluorescence using the 488-nm line from an argon ion laser and two photodetectors (530/30 nm for FITC fluorescence and 580/30 nm for PKH-26 fluorescence). A l 0 0 X objective in conjunction with an 80-pm pinhole aperture allowed for detection of optical sections of the fluorescence image that were 0.3-pm thick (full width at half-maximum intensity). Representative images were selected from the slices through the center of the M 0 after sectioning the entire cell in 1-pm steps. (Fig 2) . Immediately after the addition of target cells to MDM0 (time 0 ,  Fig 2A) , all target cells (PKH-26 stained malignant lymphocytes) were located in quadrant 4 (lower right) of the contour plot and all effector cells (anti-CD14-FITC-labeled M D M 0 ) were located in quadrant 1 (upper left). Negligible phagocytosis occurred at time 0, as evidenced by the lack of dual-positive events in quadrant 2 (upper right). After incubation for 1 hour without BsAb (Fig 2B) , approximately 14% of the target cells had shifted to quadrant 2, representing CD14+ MDM0 that had nonspecifically ingested PKH-26-stained targets. Addition of either the anti-CD 19xMoAb22 (Fig 2C) or the anti-CD37xMoAb22 (Fig 2D) BsAb significantly increased phagocytosis, shifting the proportion of target cells from quadrant 4 to quadrant 2. In this particular experiment, after 1 hour of incubation at an effector to target ratio of 1O:l and BsAb concentration of 0.1 pg/mL, 51% (Fig 2C, anti-CD19xMoAb22 ) and 53% (Fig 2D, antiCD37xMoAb22 ) of the target cells were phagocytized.
RESULTS

Phagocytosis
Routinely, the amount of BsAb-mediated phagocytosis was calculated by subtracting the amount of nonspecific phagocytosis from the total phagocytosis, for results of 38% and 39%, respectively, in this example.
In a standard experimental design, effectors and targets were mixed in the presence of BsAb and incubated for 60 minutes. To confirm that, under these conditions, the flow cytometric assay was measuring phagocytosis of target cells by MDM0 and not conjugate formation between the target and effector cells without internalization, representative samples were examined by light and fluorescent microscopy. For example, in an experiment with the anti-CD19xMoAb22 BsAb, 100 dual-positive cells from each of 6 samples were examined.
Kinetic analysis of BsAb-mediated phagocytosis.
For Of these 600 cells, 88.5% 2 1.3% showed evidence of phagocytosis, whereas the remainder appeared to be conjugates. Similar results were obtained with the antiCD37xMoAb22 BsAb, ie, 88.0% ? 0.9%. Routinely, greater than 85% of the dual-positive MDM0 exhibited evidence of tumor cell ingestion. The kinetics of BsAb-mediated phagocytosis of malignant lymphocytes was examined next by flow cytometry and confocal microscopy. Targets, stained with PKH-26, and effectors were combined in the presence of BsAb and incubated 30, 60, or 360 minutes before stopping the reaction by placing the samples on ice. Samples were labeled with anti-CD14 Fl[TC and analyzed by flow cytometry. In the absence of BsAb, nonspecific phagocytosis increased from 6% at 30 minutes to 29% at 360 minutes. Maximum BsAb- mediated phagocytosis occurred by 60 minutes (antiCD19xMoAb22,41%; anti-CD37xMoAb22, 50%), and the additional phagocytosis detected at 360 minutes was attributable entirely to the increased nonspecific phagocytosis.
Dual-positive cells from each time point were sorted by flow cytometry and sectioned by confocal microscopy. Representative images, through the MDMQI center, are shown in Fig 3. The images depict clearly the process of target cell binding, target cell ingestion, and target cell destruction over a 6-hour period. After 30 minutes, 60% of the target cells examined in this manner were bound to the surface of effector cells, whereas the other targets were either completely ingested or in the process of being internalized. After 60 minutes, 86% of targets had been phagocytized and appeared as either an intact cell (33%) or as decomposed material 30 min 60 min 360 min (67%) in the effector cells. By 360 minutes, no conjugates were seen in any of the images and 80% of the doublepositive images showed internalized debris, whereas the remaining images were of intact phagocytized targets. Figure 4 shows the effective concentration range of BsAb required for phagocytosis. Optimal BsAb-mediated phagocytosis plateaued over a broad concentration range. Maximum phagocytosis with anti-CD 19xMoAb22 and anti-CD37xMoAb22 occurred at a concentration of 0.01 and 0.1 pg/mL, respectively. Large amounts of either BsAb were less effective, because at these concentrations both effector target cells were saturated with BsAb without cross-linking their receptors. In other studies, we mixed both BsAbs over a wide concentration range and determined that at lower, but not higher, concentrations their combined effects were additive (data not shown).
The effect of cytokines on BsAbmediated phagocytosis was examined next. In these experiments, MDM0 were cultured free of cytokines or were exposed to either lFNy (40 U/mL) alone or IFNy in combination with M-CSF (100 ng/mL) for 18 hours. Before the phagocytosis assay, MDMB were washed free of cytokines to eliminate the potential tumoricidal effects of IFNy. Fresh M-CSF (as indicated), BsAb anti-CD37xMoAb22 at 1.0 pg/ mL, and malignant lymphocyte targets were then added in sequence to the MDMB effectors. Results (Fig 5 ) show that prior activation with IFNy alone or IFNy with M-CSF significantly (P < .05) enhanced phagocytosis as compared with those effectors treated with neither lFNy nor M-CSF. Moreover, lFNy priming with M-CSF enhanced phagocytosis to a greater degree than did IFNy alone.
In a series of blocking studies, we confirmed that BsAb-mediated phagocytosis was mediated through FcyRl and was not inhibited by human IgG. MoAb22 is reactive with FcyRI at an epitope distinct from the ligand binding site," whereas both human IgGl and the Phagocytosis with BsAbs constructed from MoAb22 was mediated through FcyRl and was not blocked by autologous serum, polyclonal IgG, or monomeric lgG1. MDMB were incubated with malignant lymphocytes and either whole MoAb or BsAb for l hour. In the presence of autologous serum, polyclonal IgG, and monomeric human IgG1, MoAb-mediated phagocytosis was competitively inhibited because both CD19 and CD37 MoAbs are of an isotype (lgG2a) whose Fc domain preferentially binds to FcyRI. Autologous serum, polyclonal IgG, and monomeric human lgGl did not block BsAbmediated phagocytosis because MoAb22 recognizes an epitope outside the ligand binding domain. This indicates that BsAbs constructed with MoAb22 will be able t o circumvent the inhibitory effect that human IgG has on FcyRI-dependent functions in vivo.
For .-
blocked BsAb-mediated phagocytosis with either BsAb. This indicates that BsAbs constructed from MoAb 22 will be able to circumvent the inhibitory effect that human IgG has on FcyRI-dependent function in vivo and suggests that receptor cross-linking, and not occupancy of the ligand binding site, is the principal signal required to initiate FcyRI function.
To definitively establish that both BsAbs were triggering phagocytosis through FcyRI, the following FcyR blocking agents were examined (Fig 7) : MoAb22 F(ab'),, MoAb IV.3, MoAb 3G8, and MoAb 197. As expected, BsAb-mediated phagocytosis was blocked by MoAb22 F(ab'), antibody fragments. These fragments target the same FcyRl epitope recognized by the MoAb22 arm of the BsAbs and confirms that the MoAb22 portion of both BsAbs was triggering phagocytosis. MoAb22 fragments did not block phagocytosis mediated by whole antLCD37 or anti-CD19 (data not shown). Neither MoAb IV.3, which blocks FcyRII, nor MoAb 3G8, which blocks FcyRIII, interfered with antibody-mediated phagocytosis. Thus, phagocytosis mediated by these BsAbs and MoAbs is through FcyRI only. Finally, the ability of MoAb 197 to inhibit phagocytosis was examined. MoAb 197 will effectively cross-link all FcyRl on a cell by binding through its Fc domain to the ligand binding site and through its Fab domain to the external epitope. The external epitope recognized by MoAb 197 differs from the site recognized by MoAb22. In the presence of MoAb 197, phagocytosis by both BsAbs was effectively blocked, further confirming that they were triggering through FcyRI.
The susceptibility of malignant B cells from patients with circulating lymphoma cells or CLL was also examined using the phagocytosis assay (Fig 8) . Four samples were from patients with CLL (P61 through P64). and one each was from a patient with prolymphocytic leukemia (P49) and a patient with mantle cell lymphoma in a leukemic phase (P24). All patientderived material expressed CD37 and CD19 on the surface of the malignant B cells. In all six samples, patient-derived lymphocytes were susceptible to a significant degree of BsAb-mediated phagocytosis by both BsAbs. Significantly more ( P < .OS) phagocytosis was observed with antiCD37xMoAb22 than with anti-CD 19xMoAb22.
Phagocytosis of patient-derived material. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From targeting molecule designed to direct M 0 killing and/or phagocytosis of the tumor cells. The BsAb used in our investigations targeted lymphoma cells to a potent cytolytic trigger molecule, FcyWCD64, that is expressed exclusively by monocytes, M a , myeloid precursors, dendritic cells, and activated neutrophil^.'^.^^.^^,'^ In a patient population that is frequently lymphopenic due to prior therapy or the disease itself and in which early MoAb studies have shown that immunotherapy is most effective in a minimal residual disease ie, immediately after chemotherapy or bone marrow transplant when most potential effector cells are unlikely to be available, the M 0 has the advantage of accessibility and functional integrity. Tissue M a have been shown to remain functional throughout transplant. As measured by the clearance of anti-D coated red blood cells, M 0 are capable of supporting ADCC at day 0 of bone marrow transplantation, with increased capabilities during the first month of re~overy.~' Furthermore, with respect to tumor killing, monocytes are fully functional even in the early posttransplantation period,"' ie, before day 100 posttransplantation. Thus, our experiments were designed to determine whether the theoretical advantage of using the M 0 could be realized and improved on when armed with BsAb.
Antibody-dependent phagocytosis of tumor cell lines (breast, neuroblastoma, and melanoma) by MDM0 acting through the low-affinity Fc receptors (FcyRII and FcyRIII) has been shown by Munn et al. 34 The high-affinity FcyRI has also been shown to trigger phagocytosis of human erythrocytes sensitized with human IgG.41 Antibody-mediated external lysis of both malignant and nonmalignant target cells by FcyRI and FcyRII on the monocyte and all three FcyR on M 0 is well documented. van de Winker' has shown that, although both FcyRI and I1 can mediate ADCC measured by 51Cr release, a much higher degree of target sensitization is necessary for FcyRII-than for FcyRI-mediated ADCC.
In the studies reported here, we examined the ability of two BsAbs to mediate phagocytosis of patient-derived malignant B cells. Both BsAbs were constructed by chemically linking the Fab portion of MoAb22, an antibody that reacts with the high-affinity FcyRI to the Fab portion of MoAbs recognizing the B-cell differentiation antigens CD19 and CD37. The widespread expression of both CD19 and CD37 on B-cell NHLs and chronic leukemias and their absence from hematopoietic cells, including platelets and stem cells, makes them especially suitable targets for therapy. In vitro, the anti-CD19xMoAb22 and the anti-CD37xMoAb22 BsAbs effectively mediated phagocytosis by MDM0 of patient tumor cells. Moreover, preincubation of M 0 with IFNy alone or IFNy with M-CSF enhanced BsAb-mediated phagocytosis. As expected, phagocytosis by these BsAbs was not inhibited in the presence of whole serum, the polyclonal gammaglobulin fraction, or the monomeric IgGl fraction because MoAb22 reacts with FcyRI at an epitope outside the ligand binding site. This indicates that these and other BsAbs constructed with MoAb22 will be able to circumvent the inhibitory effect that human IgG has on FcyRI-dependent function in vivo. BsAb-mediated phagocytosis was blocked by antibodies that target or sterically hinder binding to the FcyRI epitope recognized by MoAb22. Independently, both BsAbs were effective against a number of patient-derived tumors.
Our experiments show that BsAb-mediated phagocytosis through FcyRI must be considered an important and efficacious killing mechanism of the M 0 that may be POtentially harnessed against malignant lymphoma cells. We have developed another BsAb, MDX-210, an Fab X Fab (520C9xMoAb22) construct combining specificity for human CD64 (FcyRI) and the HER-2/neu oncogene product.24 In vitro data show that MDX-210 facilitates ADCC and phagocytosis of HER-2/neu-positive targets and stimulates release of monocyte/M@-derived cytokines. Based on these encouraging observations, phase I studies have been undertaken in women with breast or ovarian cancer and in men with prostate cancer. To date, treatment with this BsAb has been well tolerated. The most common toxicity was grade 1 to 2 fevers and malaise. Hypotension also developed in some patients, persisting for 3 to 6 hours at lower doses and for up to 12 to 20 hours at higher doses.
Biologic effects of MDX-210 in these phase 1 studies included greater than 80% saturation of monocyte FcyRI receptors at doses greater than 3.5 mg/m2. Peak plasma levels in excess of 1 mg/mL were achieved, which is a substantially greater concentration than required for optimal monocyte/ M 0 activation in vitro. MDX-210 was immunologically active and induced increased plasma levels of TNFa, interleukin-6, granulocyte colony-stimulating factor (G-CSF), and neopterin. MDX-210 induced one partial response and one mixed response among 10 patients with breast cancer who were evaluable for response. Moreover, treatment with MDX-210 resulted in an increase in antitumor antibodies in the circulation of approximately 30% of the patients treated, suggesting a vaccine-like effect of this therapy.
Overall, the in vitro results presented here indicate that either anti-CD19 or anti-CD37 containing BsAb is an excellent candidate for clinical trials of NHL and may be particularly effective when used in combination with hematopoietic growth factors or ex vivo-activated myeloid cells. Moreover, the encouraging results of recent clinical trials using a similar BsAb justify undertaking a clinical trial using FcyRI-targeted BsAbs in patients with NHL with disease resistant to standard chemotherapeutic agents or with organ and marrow toxicity that precludes the use of standard agents. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
